Physician profile
Tamara Lieberman
NPI 1912029463
$5,088.70
in general payments reported to CMS, 2019-2025
46 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $865 · 2020: $749 · 2021: $936 · 2022: $1,176 · 2023: $540 · 2024: $534 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,362.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,263.74 | 2019-2025 | |
| Amgen INC. | $737.87 | 2019-2025 | Evenity, Prolia, Prolia |
| Novo Nordisk INC | $392.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $240.99 | 2019-2025 | Xifaxan |
| Allergan, INC. | $236.89 | 2019-2020 | |
| Abbott Laboratories | $203.86 | 2020-2024 | Assurity, Octrode |
| Takeda Pharmaceuticals U.S.A., INC. | $202.94 | 2019-2025 | Trintellix |
| Pfizer INC. | $172.53 | 2019-2025 | |
| Lilly USA, LLC | $171.50 | 2019-2024 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $161.25 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Amarin Pharma, INC. | $84.46 | 2019-2022 | |
| Exact Sciences Corporation | $75.02 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $72.69 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $67.79 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.79 | 2019-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Lieberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.